X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (383701) 383701
Newspaper Article (31480) 31480
Newsletter (4207) 4207
Book Chapter (2623) 2623
Web Resource (1645) 1645
Dissertation (799) 799
Magazine Article (270) 270
Publication (217) 217
Book / eBook (145) 145
Trade Publication Article (129) 129
Conference Proceeding (118) 118
Government Document (104) 104
Reference (30) 30
Book Review (24) 24
Streaming Video (15) 15
Paper (3) 3
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (295808) 295808
life sciences & biomedicine (262119) 262119
humans (198563) 198563
animals (172381) 172381
kinases (138287) 138287
proteins (85062) 85062
mice (79624) 79624
phosphorylation (76078) 76078
oncology (75685) 75685
male (72822) 72822
signal transduction (70352) 70352
cell biology (66090) 66090
female (62170) 62170
biochemistry & molecular biology (59991) 59991
apoptosis (57583) 57583
gene expression (50797) 50797
rats (47504) 47504
research (46549) 46549
cell line, tumor (45537) 45537
cancer (45522) 45522
cells, cultured (40623) 40623
research article (37451) 37451
mutation (34771) 34771
cell cycle (32628) 32628
science & technology - other topics (32537) 32537
multidisciplinary sciences (31899) 31899
signal transduction - drug effects (31475) 31475
cell line (31418) 31418
medicine (31140) 31140
protein kinases (29612) 29612
analysis (29545) 29545
enzyme inhibitors - pharmacology (28949) 28949
rodents (28342) 28342
tumors (28072) 28072
pharmacology & pharmacy (27249) 27249
science (25334) 25334
physiological aspects (25262) 25262
cell proliferation (25201) 25201
genetic aspects (25178) 25178
middle aged (24589) 24589
health aspects (24383) 24383
neurosciences (23731) 23731
apoptosis - drug effects (23597) 23597
protein kinase inhibitors - pharmacology (23478) 23478
biology (23365) 23365
physiology (21701) 21701
neurosciences & neurology (21586) 21586
studies (21309) 21309
cell growth (20642) 20642
adult (20382) 20382
inflammation (19618) 19618
metastasis (19617) 19617
immunology (19390) 19390
blotting, western (19371) 19371
aged (19299) 19299
cancer therapies (19266) 19266
care and treatment (18937) 18937
cell proliferation - drug effects (18821) 18821
biochemistry (18373) 18373
enzymes (18340) 18340
protein-serine-threonine kinases - metabolism (18273) 18273
dose-response relationship, drug (18237) 18237
medicine, research & experimental (17913) 17913
research & experimental medicine (17893) 17893
enzyme activation (17081) 17081
rats, sprague-dawley (17057) 17057
breast cancer (16914) 16914
antineoplastic agents - pharmacology (16837) 16837
phosphorylation - drug effects (16536) 16536
genes (16463) 16463
mice, inbred c57bl (16454) 16454
abridged index medicus (16427) 16427
cytokines (16081) 16081
protein binding (15674) 15674
protein kinase c - metabolism (15546) 15546
signal transduction - physiology (15182) 15182
medical research (15178) 15178
time factors (15129) 15129
immunohistochemistry (15045) 15045
transfection (14905) 14905
hematology (14688) 14688
chemotherapy (14598) 14598
mitogen-activated protein kinases - metabolism (14431) 14431
signaling (14302) 14302
development and progression (14011) 14011
proto-oncogene proteins c-akt - metabolism (13995) 13995
tyrosine (13930) 13930
protein kinase inhibitors - therapeutic use (13928) 13928
deoxyribonucleic acid--dna (13855) 13855
stem cells (13849) 13849
tumor cells, cultured (13549) 13549
disease models, animal (13329) 13329
metabolism (13323) 13323
lung cancer (13066) 13066
transcription factors (12827) 12827
molecular sequence data (12795) 12795
binding sites (12778) 12778
life sciences (12685) 12685
chemistry (12573) 12573
phosphatidylinositol 3-kinases - metabolism (12215) 12215
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (72) 72
Gerstein Science - Stacks (34) 34
Collection Dvlpm't (Acquisitions) - Vendor file (11) 11
Chemistry (A D Allen) - Stacks (3) 3
UofT at Mississauga - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (421654) 421654
Chinese (2616) 2616
Japanese (2583) 2583
French (853) 853
German (715) 715
Russian (551) 551
Portuguese (264) 264
Spanish (199) 199
Korean (197) 197
Polish (130) 130
Czech (82) 82
Norwegian (79) 79
Hungarian (74) 74
Italian (69) 69
Dutch (50) 50
Turkish (29) 29
Ukrainian (29) 29
Danish (23) 23
Croatian (17) 17
Swedish (12) 12
Slovak (11) 11
Finnish (10) 10
Hebrew (6) 6
Bulgarian (4) 4
Serbian (4) 4
Latin (3) 3
Romanian (3) 3
Slovenian (3) 3
Persian (2) 2
Afrikaans (1) 1
Arabic (1) 1
Catalan (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 07/2017, Volume 35, Issue 19, pp. 2193 - 2202
.... We hypothesize the programmed death-ligand 1 (PD-L1) inhibitor, durvalumab, olaparib, or cediranib combinations are tolerable and active in recurrent women's cancers... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
Chemical biology & drug design, ISSN 1747-0277, 01/2011, Volume 77, Issue 1, pp. 1 - 11
The BCR‐ABL inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia... 
kinase | ponatinib | AP24534 | drug discovery | X‐ray crystallography | structure‐based drug design | X-ray crystallography | Structure-based drug design | Drug discovery | Ponatinib | Kinase | Pharmacology & Pharmacy | Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Chemistry, Medicinal | Science & Technology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Piperazines - chemistry | Structure-Activity Relationship | Pyridazines - pharmacology | Pyridazines - chemical synthesis | Pyrimidines - chemistry | Protein Kinase Inhibitors - chemistry | Protein Binding - drug effects | Imidazoles - chemical synthesis | Imidazoles - therapeutic use | Pyridazines - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Imidazoles - pharmacology | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Animals | Mutation - drug effects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Benzamides | Fluoroimmunoassay | Fusion Proteins, bcr-abl - metabolism | Drug Resistance, Neoplasm - drug effects | Drug resistance | Analysis | Leukemia | Index Medicus | STRUCTURE-ACTIVITY RELATIONSHIPS | MUTANTS | BASIC BIOLOGICAL SCIENCES | ENZYME INHIBITORS | TYROSINE | GENE MUTATIONS | PHOSPHOTRANSFERASES | MYELOID LEUKEMIA | MUTATIONS | ANTINEOPLASTIC DRUGS | 60 APPLIED LIFE SCIENCES | RESIDUES
Journal Article
The New England journal of medicine, ISSN 1533-4406, 04/2015, Volume 372, Issue 18, pp. 1689 - 1699
AZD9291, an irreversible inhibitor of epidermal growth factor receptor, was associated with tumor responses in the majority of patients with advanced non... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aniline Compounds - administration & dosage | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Aniline Compounds - pharmacokinetics | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Patient outcomes | Tyrosine | Appetite | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Diarrhea | Nausea | Drug resistance | Kinases | Patients | Epidermal growth factor | Pharmacokinetics | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
International journal of cancer, ISSN 0020-7136, 08/2015, Volume 137, Issue 3, pp. 686 - 697
Around 70% of breast cancers express the estrogen receptor α (ERα) and depend on estrogen for growth, survival and disease progression. The presence of hormone... 
Her2 inhibition | proteasome inhibition | estrogen receptor alpha inhibition | Life Sciences & Biomedicine | Oncology | Science & Technology | Receptors, Estrogen - metabolism | Prognosis | TOR Serine-Threonine Kinases - metabolism | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Agents - therapeutic use | Phosphatidylinositol 3-Kinases - metabolism | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Tumor Suppressor Protein p53 - genetics | Breast Neoplasms - metabolism | Neoplasm Metastasis | Receptor, Epidermal Growth Factor - metabolism | Estrogen Receptor alpha - metabolism | Female | Antineoplastic Agents - pharmacology | Cell Death - drug effects | Gene Expression Regulation, Neoplastic - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Disease Models, Animal | Bortezomib | Receptors, Estrogen - genetics | Proteasome Inhibitors - pharmacology | Signal Transduction | Tumor Suppressor Protein p53 - metabolism | Breast Neoplasms - drug therapy | Proteasome Inhibitors - therapeutic use | Xenograft Model Antitumor Assays | Animals | Breast Neoplasms - pathology | Cell Line, Tumor | Breast Neoplasms - mortality | Pyrazines - pharmacology | Boronic Acids - pharmacology | Mitogen-Activated Protein Kinases - metabolism | Estrogen | Phenols | Development and progression | Breast cancer | Hormones | Tumor proteins | Medical prognosis | Mortality | Endocrine therapy | Mammography | Kinases | Cancer therapies | Tumors | Index Medicus
Journal Article
PloS one, ISSN 1932-6203, 02/2017, Volume 12, Issue 2, pp. e0171221 - e0171221
Journal Article
International journal of cancer, ISSN 0020-7136, 01/2018, Volume 142, Issue 1, pp. 202 - 213
...) inhibitor ibrutinib, have demonstrated notable therapeutic effects in relapsed/refractory patients, which indicate that pharmacological inhibition of BCR pathway holds promise in MCL treatment... 
mTOR inhibitor | targeted therapy | BTK inhibitor | drug combination | Mantle cell lymphoma